Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation

Su2069 How Effective Is Prucalopride for the Treatment of Chronic Constipation? A Systematic Review and Meta-Analysis

(2015) Luigi Gatta et al.   GASTROENTEROLOGY

Randomised clinical trial: macrogol/PEG 3350+electrolytes versus prucalopride in the treatment of chronic constipation - a comparison in a controlled environment

(2013) R. Cinca et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Systematic review: cardiovascular safety profile of 5-HT4 agonists developed for gastrointestinal disorders

(2012) J. Tack et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Prucalopride: evaluation of the pharmacokinetics, pharmacodynamics, efficacy and safety in the treatment of chronic constipation

(2012) Jan Tack et al.   Expert Opinion on Drug Metabolism & Toxicology

Prucalopride in the treatment of chronic constipation in patients from the Asia-Pacific region: a randomized, double-blind, placebo-controlled study

(2012) M. Ke et al.   NEUROGASTROENTEROLOGY AND MOTILITY

Prevalence of and Risk Factors for, Chronic Idiopathic Constipation in the Community: Systematic Review and Meta-analysis

(2011) Nicole C Suares et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis

(2011) A. C. Ford et al.   GUT

Inclusion criteria for pharmacodynamic and clinical trials in chronic idiopathic constipation: pitfalls in using Rome III for functional constipation

(2011) Michael Camilleri   Therapeutic Advances in Gastroenterology

Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation - follow-up of patients from the pivotal studies

(2010) M. Camilleri et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation - a 4-week, randomized, double-blind, placebo-controlled, dose-response study

(2010) M. Goldberg et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Prucalopride for constipation

(2010) Michael Camilleri et al.   EXPERT OPINION ON PHARMACOTHERAPY

905 A Novel Gastrointestinal Prokinetic, ATI-7505, Increased Spontaneous Bowel Movements (Sbms) in a Phase II, Randomized, Placebo-Controlled Study of Patients With Chronic Idiopathic Constipation (CIC)

(2010) Monica Palme et al.   GASTROENTEROLOGY

5-HT4 receptor agonists: similar but not the same

(2010) J. H. De Maeyer et al.   NEUROGASTROENTEROLOGY AND MOTILITY

A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation

(2010) S. Müller-lissner et al.   NEUROGASTROENTEROLOGY AND MOTILITY

Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study

(2009) m. camilleri et al.   NEUROGASTROENTEROLOGY AND MOTILITY

Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation - a 12-week, randomized, double-blind, placebo-controlled study

(2008) E. M. M. QUIGLEY et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Why Most Discovered True Associations Are Inflated

(2008) John P. A. Ioannidis   EPIDEMIOLOGY

Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives

(2008) J Tack et al.   GUT

The in vitro pharmacological profile of TD-5108, a selective 5-HT4 receptor agonist with high intrinsic activity

(2008) J. A. M. Smith et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

The in vivo gastrointestinal activity of TD-5108, a selective 5-HT4 receptor agonist with high intrinsic activity

(2008) D. T. Beattie et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

A Placebo-Controlled Trial of Prucalopride for Severe Chronic Constipation

(2008) Michael Camilleri et al.   NEW ENGLAND JOURNAL OF MEDICINE